VAUGHAN, Ontario / Jan 23, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, Feb. 22, 2023 |
Time: | 8:00 a.m. ET |
Webcast: | |
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) |
Participant Access Code: | 681651 |
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) |
Replay Passcode: | 47443 (replay available until March 8, 2023) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
© 2022 Bausch & Lomb Incorporated or its affiliates.
Last Trade: | US$16.85 |
Daily Change: | -0.22 -1.29 |
Daily Volume: | 844,772 |
Market Cap: | US$5.930B |
January 13, 2025 December 11, 2024 October 30, 2024 October 14, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load